secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivos Therapeutics, Inc. (VVOS)
CIK:        0001716166
Form:       8-K
Filed at:   2026-10-15T12:45:26+00:00
Accession:  0001493152-26-047158
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Vivos Therapeutics to issue $12M Series C preferred for 11% SOD Sciences stake and 50% test co-ownership
--------------------------------------------------------------------------------

- Vivos will issue 12,000 Series C Convertible Preferred shares with $1,000 stated value each, totaling $12 million, to SOD Sciences.
- Consideration includes 2,907,338 SOD common shares, at least 11% fully diluted, and a 50% undivided interest in SOD's pseudohypoxia test IP.
- Series C preferred is convertible at fixed $0.15 per share into up to 80 million common shares, subject to a 19.99% exchange cap.
- Nasdaq minimum $2.5 million stockholders' equity compliance: pro forma equity of about $8 million exceeds requirement by $5.5 million after the deal.
- Closing expected October 15, 2026, subject to independent valuation, auditor concurrence, Streeterville Capital consent, Nasdaq notification, and SOD consents.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716166/000149315226047158/0001493152-26-047158-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716166/000149315226047158/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-047158

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer